J&J acquires neuroscience company Intra-Cellular Therapies for USD 14.6 billion
Pharmaceutical giant Johnson & Johnson buys Intra-Cellular Therapies, a long-term core holding of Arctic Aurora LifeScience and Arctic Aurora Biotech Select, at a 39% premium.
The beginning of the year is an exciting time for everyone, but even more so for biotech investors. It is usually in the first few weeks of January that biotech executives and investors gather at the JP Morgan Healthcare Conference to set the outlook for the year. Historically, the conference has been an ideal venue for announcing major deals and partnerships, giving the sector a sentiment boost at the start of the year.
In 2025, J&J and Intra-Cellular Therapies announced the largest deal to date. Intra-Cellular Therapies has long been a core holding in both our portfolios, driven by its leading position in neuroscience. The company's lead drug, Caplyta, is approved for bipolar depression and schizophrenia and is currently under review for major depressive disorder. With millions of people suffering from these diseases, Caplyta offers a new option to alleviate the symptoms of these conditions without the side effects of previous depression and schizophrenia drugs, such as weight gain and other metabolic effects. As a result of these factors, Caplyta has shown increasing sales and exceptional prescribing trends since its approval in late 2019. This led management to announce peak sales expectations of USD 5 billion last year.
This acquisition reflects the growing focus of pharmaceutical companies on neuroscience and mental health, two previously neglected areas with large patient populations and very limited new treatment options over the past 10-20 years. Bristol Myers Squibb's USD 14 billion acquisition of our former portfolio holding Karuna Therapeutics was also part of this pattern.
As pharmaceutical companies approach the patent expiry of their largest products, they typically replenish their pipelines by acquiring innovative biotech companies. The growing cash piles of the big pharma companies combined with the upcoming patent cliffs usually lead to increased deal-making activity, which could provide a tailwind for the biotech industry.
With more than 20 takeouts in the fund's history, Arctic Aurora's portfolio management team has a strong track record of generating excess returns by identifying takeout candidates in the biopharma space.
Latest news
Arctic Asset Management - Revolution Medicines announced unprecedented Phase 3 results in pancreatic cancer
Arctic Aurora LifeScience holding, Revolution Medicines announced outstanding overall survival benefit in metastatic pancreatic cancer, one of the most lethal tumors.
Arctic Asset Management - Markedskommentar mars 2026
Markedene i mars ble påvirket av krigen i Iran som har spredt seg til store deler av Midtøsten og skapt betydelige globale ringvirkninger. Etter at USA og Israel angrep Iran på den siste dagen i februar, har regionen vært preget av krigshandlinger, med påfølgende avbrudd i råvareproduksjon og forsyningskjeder som har gitt økt markedsvolatilitet.
Arctic Asset Management - No slowing down of Biotech M&A: Soleno to be acquired by Neurocrine
On April 6, Arctic Aurora LifeScience holdings Soleno Therapeutics and Neurocrine Biosciences announced an agreement in which the mid-cap commercial biotech Neurocrine acquires Soleno for USD 2.9 billion or USD 53 per share - a 34% premium over the last closing price.
Arctic Asset Management - Apellis to be acquired by Biogen for 140% premium
On March 31, Arctic Aurora LifeScience portfolio company Apellis Pharmaceuticals announced that the company had agreed to be acquired by Biogen for an upfront cash consideration of USD 5.6 billion, representing a 140% premium on the latest closing price.
Arctic Asset Management - Arctic Midt i Måneden - Global uro, energisjokk og markedsmuligheter
Geopolitisk uro, stigende energipriser og økt markedsvolatilitet preger finansmarkedene i mars. Hva betyr dette for renter, aksjer og investorers posisjonering fremover? I denne episoden av Arctic Midt i Måneden diskuterer Albert Collett sammen med Cathrine Foyn, Tone Varmann og Alexander Larstedt Lager hvordan krig og usikkerhet påvirker markedene – og hvor mulighetene kan ligge i en urolig tid.
Arctic Asset Management - Unlocking Alpha in Biotech Through Active Selection
Yesterday, two companies in the Arctic Aurora LifeScience portfolio reported positive clinical data, which was rewarded by the market. Clinical execution and identifying companies with differentiated drug candidates yields excess returns, as demonstrated by Xenon's share price, which appreciated by close to 50% on positive data, and Dianthus, which appreciated by 21%.